Skip to main content
Article thumbnail
Location of Repository

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

By Chantal Mathieu and Evy Degrande

Abstract

Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose. An extensive clinical program involving approximately 22,000 patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well tolerated and efficacious in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy. Studies of vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2663430
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    2. (2002). Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fi xed-dose combination therapy. Clin Ther,
    3. (2007). Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    4. (2008). Bioequivalence of vildagliptin/ metformin fi xed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
    5. (2008). Characterization of the infl uence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia.
    6. (2007). Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes. Diabet Med,
    7. (2008). Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med,
    8. (2007). Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care,
    9. (2006). Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetes. Diabetologia, 49(suppl 1):110–1. Abstract 0174.
    10. (2007). Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    11. (2008). DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci,
    12. (2008). Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fi xeddose combination tablet in healthy volunteers.
    13. (1998). Effect of intensive blood-glucose control with metformin on complications
    14. (2007). Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    15. (2007). Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes.
    16. (2008). Effects of the dipeptidyl peptidase inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    17. (2008). Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab, Feb 18 [Epub ahead of print].
    18. (2007). Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care,
    19. (2007). Effi cacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    20. (2007). Effi cacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab,
    21. (2008). Effi cacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab,
    22. (2007). Effi cacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract,
    23. (2002). Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
    24. (2008). Eucreas [package insert].
    25. (2007). Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
    26. (2008). Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab, Mar 18 [Epub ahead of print].
    27. (2008). Galvus [package insert].
    28. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    29. (2003). Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin.
    30. (2005). Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care,
    31. (2004). Incretins, insulin secretion and type 2 diabetes mellitus.
    32. (2004). Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes.
    33. (2006). Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care,
    34. (2008). Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    35. (2008). Metab, 5:424–31.Vascular Health and Risk Management 2008:4(6) 1359 Vildagliptin oral treatment for T2DM Bolli
    36. (2007). Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
    37. (2007). Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet,
    38. (2004). Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.
    39. (2006). Restoration of an acute insulin response to glucose (AIRg) in drug naïve patients with type 2 diabetes (T2DM) by 3-month treatment with vildagliptin. Diabetes, 55(suppl 1): A108. Abstract 454-P.
    40. (2007). Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD),
    41. (2008). Sustained effi cacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res,
    42. (2007). The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet,
    43. (2006). The biology of incretin hormones.
    44. (2007). The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    45. (2008). The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care,
    46. (2008). The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
    47. (2007). The infl uence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
    48. (2008). The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    49. (2006). Therapeutic approaches to preserve islet cell mass in type 2 diabetes. Annu Rev Med,
    50. (2004). Therapeutic strategies based on glucagon-like
    51. (2006). Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not
    52. (2007). Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebocontrolled study. Diabetes Obes Metab,
    53. (2007). Vildagliptin in drugnaïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res,
    54. (2007). Vildagliptin signifi cantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin [abstract]. Diabetes, 56(suppl 1): A139. Abstract 521-P.
    55. (2006). Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    56. (2005). Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
    57. (2008). Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.